Thermo Fisher Scientific, a global leader in scientific research solutions, has introduced cutting-edge solutions aimed at enhancing research workflows to expedite the promise of precision medicine. Unveiled at the annual American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics in Anaheim, California, these innovative mass spectrometry and chromatography instruments, along with software solutions, empower researchers to achieve deeper analytical insights with unparalleled flexibility, thereby enhancing productivity, efficiency, and accelerating translational research workflows.

“As we strive to meet the evolving needs of our customers, we recognize the demand for purpose-built solutions tailored to their specific application areas, facilitating the transition of key findings from compounds to clinical research,” remarked August Specht, Vice President of Research and Development, Chromatography and Mass Spectrometry at Thermo Fisher Scientific. “By integrating our industry-leading instruments with best-in-class software solutions and workflows, we aim to deliver on this commitment, enabling today's crucial research findings to pave the way for the precision medicines of tomorrow.”

Accelerating Research from Discovery to Validation

In advancing scientific discovery, the Thermo Scientific Orbitrap™ Astral™ mass spectrometer has been complemented by the introduction of the Thermo Scientific Stellar™ MS, revolutionizing translational omics research on an unprecedented scale. The Stellar MS enhances biomarker verification by providing rapid and sensitive quantitation, ensuring the confirmation and verification of all significant biomarkers. With its unique design, which combines the quantitative performance of a triple quadrupole with the single-cell sensitivity of linear ion trap analyzers, the Stellar MS achieves 10 times the quantitative sensitivity for five times more compounds at scale compared to existing technologies.

To address the growing demand for liquid chromatography-mass spectrometry (LC-MS)-based omics, the new Thermo Scientific Vanquish™ Neo ultra-high performance liquid chromatography (UHPLC) system Tandem Direct Injection workflow enables proteomics labs to rapidly generate high-quality, biologically relevant data. This workflow increases sample throughput, providing up to a ~70% increase in samples per day, while reducing carryover and yielding over 90% mass spectrometer utilization, thereby facilitating high-throughput LC separation as an ideal complement to high-throughput mass spectrometers such as Orbitrap Astral MS or Stellar MS.

The Next-Generation Workflow Starts with Built-for-Purpose Technology

In a bid to accelerate research endeavors, Thermo Fisher Scientific has introduced three new built-for-purpose editions of the Thermo Scientific Orbitrap Ascend Editions Tribrid™ mass spectrometers, each offering unique capabilities tailored to specific application areas. These editions—MultiOmics Edition, Structural Biology Edition, and BioPharma Edition—feature new hardware for a Native MS option and a dry pump with improved sustainability and performance.

Scientists can now quantify more samples at lower concentrations using intelligent acquisition, achieving greater coverage that delivers ultimate experimental throughput, versatility, and ease of use, thereby empowering scientists to make breakthrough discoveries more efficiently.

As a complement to the Orbitrap Ascend Editions Tribrid MS, customers will soon experience the power of higher multiplexing with the launch of the Thermo Scientific TMTpro 32plex Label Reagents, enabling the analysis of up to 32 samples in a single LC-MS injection. This higher level of multiplexing is particularly beneficial for applications requiring higher throughput and depth of coverage such as chemoproteomics, peptidomics, and single-cell proteomics.

Establishing a Holistic, Reliable & Secure Software Ecosystem

Recognizing laboratories' focus on increasing productivity, Thermo Fisher Scientific has developed the Thermo Scientific Ardia™ platform, which supports end-to-end workflows and centralizes data and instrument management across multiple chromatography and mass spectrometry systems. The platform now includes new capabilities focused on security, connectivity, and openness, with enhanced support for the Orbitrap Astral MS and Stellar MS.

The newly connected Compound Discoverer 3.4 software and support for third-party Skyline.ms software, along with updates to Ardia Core 1.1 SW, Proteome Discoverer 3.2 software, and Ardia Platform Data Sync tool 1.1 software, bring enterprise-level data handling capabilities that enable users to manage, process, and share data in previously unimaginable ways. These advancements in data security and connectivity empower scientists to break down silos and gain a deeper understanding of new diagnostics and therapies at an accelerated pace.